References
- Hedon B, Hugues JN, Emperaire JC, et al. A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum Reprod 1998;13:2688–92
- Daya S. Follicle-stimulating hormone in clinical practice: an update. Treat Endocrinol 2004;3:161–71
- Bassett RM, Driebergen R. Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod Biomed Online 2005;10:169–77
- Driebergen R, Baer G. Quantification of follicle stimulating hormone (follitropin alfa): is in vivo bioassay still relevant in the recombinant age? Curr Med Res Opin 2003;19: 41–6
- Calaf Alsina J, Ruiz Balda JA, Romeu Sarrio A, et al. Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the 10–50 study, a prospective, observational, multicentre, open trial. Br J Obstet Gynaecol 2003;110:1072–7
- Zorn JR, Coffineau A, Abirached F, et al. Acceptability and value of autoinjection of gonadotropins for ovarian stimulation in intrauterine insemination. Gynecol Obstet Fertil 2001;29: 662–7
- Lakha F, Henderson C, Glasier A. The acceptability of self-administration of subcutaneous Depo-Provera. Contraception 2005;72:14–8
- Bahamondes L, Marchi NM, Nakagava HM, et al. Self-administration with UniJect of the once-a-month injectable contraceptive Cyclofem. Contraception 1997;56:301–4
- Korytkowski M, Bell D, Jacobsen C, et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836–48
- Martin JM, Llewelyn JA, Ristic S, et al. Acceptability and safety of a new 3.0 mL re-usable insulin pen (HumaPen) in clinical use. Diabetes Nutr Metab 1999;12:306–9
- Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26:1498–505
- Bohannon NJ, Ohannesian JP, Burdan AL, et al. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0 mL prefilled pen device for insulin delivery. Clin Ther 2000;22:1049–67
- Pang S, Kaplan B, Karande V, et al. Administration of recombinant human FSH (solution in cartridge) with a pen device in women undergoing ovarian stimulation. Reprod Biomed Online 2003;7:319–26
- Kettel LM, Scholl G, Bonaventura L, et al. Evaluation of a pen device for self-administration of recombinant human FSH in clomiphene citrate-resistant anovulatory women undergoing ovulation induction. Reprod Biomed Online 2004;9:373–80
- Platteau P, Laurent E, Albano C, et al. An open, randomized single-centre study to compare the efficacy and convenience of follitropin beta administered by a pen device with follitropin alpha administered by a conventional syringe in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2003;18:1200–4
- Craenmehr E, Bontje PM, Hoomans E, et al. Follitropin-beta administered by pen device has superior local tolerance compared with follitropin-alpha administered by conventional syringe. Reprod Biomed Online 2001;3:185–9
- D’Eliseo PD, Blaauw J, Millicevic Z, et al. Patient acceptability of a new 3.0 mL pre-filled insulin pen. Curr Med Res Opin 2000;16: 125–33